Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02965014
Other study ID # R01DA041009
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date January 18, 2017
Est. completion date March 17, 2020

Study information

Verified date November 2023
Source RTI International
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This three-arm cross-over randomized trial will develop, test, and compare the efficacy of two delivery formats of the Young Women's CoOp (YWC), which is designed to provide risk reduction and empowerment skills, as well as linkages to healthcare services for women who use substances. The current study will develop a revised version of the YWC and evaluate the relative efficacy of a face-to-face (face-to-face YWC), mobile Health application (mHealth YWC) delivery format, and HIV counseling and testing (HCT) as a control to reduce risky sexual behaviors and reduce substance use among young (18-25) African American women who use substances and are sexually active and have not recently been tested for HIV in three NC counties.


Description:

The purpose of this study is to use the seek, test, treat, and retain framework to develop and test the efficacy of a clinic-based, age-appropriate, woman-focused HIV risk-reduction intervention to reduce sexual risk among up to 700 young sexually active African American women aged 18 to 25 who use drugs in three North Carolina counties. The researchers will test the delivery of the woman-focused intervention conducted in two formats, face-to-face YWC and mHealth YWC, using a three-arm cross-over randomized design in which counties are randomized to (1) HCT as the control, (2) face-to-face YWC; and (3) mHealth YWC that will be delivered on tablets using an interactive app. The researchers will fulfill the purpose of this study through the following aims: (Aim 1) To develop a new YWC intervention and recruitment strategies using formative methods to engage young African American women who use substances and have not recently been tested for HIV, clinic staff, and stakeholders to ensure age appropriateness, to identify barriers to reaching these young women and the challenges in conducting the intervention in the clinics, and to develop the mHealth YWC; (Aim 2) To test the efficacy of two formats of the woman-focused intervention program (face-to-face YWC and mHealth YWC) relative to HCT with up to 700 young women aged 18 to 25 in three North Carolina county health departments for primary outcomes at 6-, and 12-month follow-up assessments; (Aim 3) To estimate the total costs of implementing the face-to-face YWC and mHealth YWC interventions, and to assess the resource components that drive these costs; and (Aim 4) To examine the extent to which the face-to-face YWC and mHealth YWC are perceived by collaborating health clinic staff and participants as being acceptable and sustainable.


Recruitment information / eligibility

Status Terminated
Enrollment 652
Est. completion date March 17, 2020
Est. primary completion date March 17, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 25 Years
Eligibility Selected Inclusion Criteria: - Identify as female - Identify as Black or African American - 18-25 years of age - Have used alcohol or drugs in greater quantity or for a longer period of time than intended within the past 30 days Exclusion Criteria: - Participants may not be non-Black/African American

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Face-to-Face Young Women's CoOp (YWC)
Participants will be offered HIV counseling and testing (HCT) and a two-session face-to-face YWC intervention. The face-to-face sessions will include information addressing the intersection of substance use, sexual risk, and violence through skill building, role-play, and rehearsal.
mHealth Young Women's CoOp (YWC)
Participants will be offered HIV counseling and testing (HCT) and training on the mHealth application, which will include all content addressed in the face-to-face YWC delivery format. Participants will also be offered a tablet to complete the two-session intervention.
HIV Counseling and Testing
Participants will be offered standard HIV counseling and testing (HCT).

Locations

Country Name City State
United States Durham County Department of Public Health Durham North Carolina
United States Guilford County Department of Public Health - Greensboro Greensboro North Carolina
United States Guilford County Department of Public Health - High Point High Point North Carolina
United States Wake County Human Services Raleigh North Carolina

Sponsors (4)

Lead Sponsor Collaborator
RTI International Durham County Department of Public Health, Guilford County Department of Public Health, Wake County Human Services

Country where clinical trial is conducted

United States, 

References & Publications (3)

Browne FA, Washio Y, Zule WA, Wechsberg WM. HIV-related risk among justice-involved young African American women in the U.S. South. Health Justice. 2023 Aug 24;11(1):32. doi: 10.1186/s40352-023-00228-7. — View Citation

Osakwe CE, van der Drift I, Opper CA, Zule WA, Browne FA, Wechsberg WM. Condom Use at Last Sex and Sexual Negotiation Among Young African American Women in North Carolina: Context or Personal Agency. J Racial Ethn Health Disparities. 2023 Jul 26. doi: 10. — View Citation

Watkins RL, Browne FA, Kizakevich PN, Howard BN, Turner LB, Eckhoff R, Wechsberg WM. An Evidence-Based HIV Risk-Reduction Intervention for Young African American Women in the US South Using mHealth: Adaptation and Development Study. JMIR Form Res. 2022 Ma — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Condomless Sex Self-reported frequency of condomless sex Baseline
Primary Condomless Sex Self-reported frequency of condomless sex 6-month follow-up
Primary Condomless Sex Self-reported frequency of condomless sex 12-month follow-up
Primary Frequency of Substance Use Frequency of using illicit drugs and alcohol Baseline
Primary Frequency of Substance Use Frequency of using illicit drugs and alcohol 6-month follow-up
Primary Frequency of Substance Use Frequency of using illicit drugs and alcohol 12-month follow-up
Secondary Increased Sexual Negotiation Self-reported ability to negotiate condom use and other safe sexual behavior with a male partner Baseline
Secondary Increased Sexual Negotiation Self-reported ability to negotiate condom use and other safe sexual behavior with a male partner 6-month follow-up
Secondary Increased Sexual Negotiation Self-reported ability to negotiate condom use and other safe sexual behavior with a male partner 12-month follow-up
Secondary Reduced Alcohol and Illicit Drug Use for a Subsample of Participants Self-reported amount of alcohol consumption and drugs used; Urine drug screen will be used to test for recent illicit drug use; Breathalyzer test results will be used to assess recent alcohol use Baseline
Secondary Reduced Alcohol and Illicit Drug Use for a Subsample of Participants Self-reported amount of alcohol consumption and drugs used; Urine drug screen will be used to test for recent illicit drug use; Breathalyzer test results will be used to assess recent alcohol use 6-month follow-up
Secondary Reduced Alcohol and Illicit Drug Use for a Subsample of Participants Self-reported amount of alcohol consumption and drugs used; Urine drug screen will be used to test for recent illicit drug use; Breathalyzer test results will be used to assess recent alcohol use 12-month follow-up
Secondary Reduced Violence and Victimization for a Subsample of Participants Self-reported experiences of emotional, physical, and sexual abuse Baseline
Secondary Reduced Violence and Victimization for a Subsample of Participants Self-reported experiences of emotional, physical, and sexual abuse 6-month follow-up
Secondary Reduced Violence and Victimization for a Subsample of Participants Self-reported experiences of emotional, physical, and sexual abuse 12-month follow-up
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02511496 - Status of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Virus (HIV) in Andalusia N/A
Completed NCT02234492 - The Effects of Statin Therapy on Coronary Flow Reserve and Inflammatory Markers in HIV-Positive Patients Phase 4
Completed NCT01685372 - Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults Phase 2
Completed NCT02027441 - Enhanced Prevention in Couples: Feasibility Study #2 N/A
Completed NCT02165202 - Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis Phase 2
Completed NCT01615601 - An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients Phase 4
Terminated NCT01448486 - A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV Phase 4
Completed NCT02572401 - Steering Together in a New Direction: Reducing the Risk of HIV/STD Among African American Men N/A
Completed NCT01449006 - A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac) Phase 4
Completed NCT04122404 - POC Strategies to Improve TB Care in Advanced HIV Disease N/A
Completed NCT03290755 - Sexual Hepatitis C in HIV Positive Men Who Have Sex With Men (MSM) in Bordeaux
Completed NCT02974998 - Cape Town Young Women's Health CoOp N/A
Completed NCT01516970 - Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r) Phase 3
Completed NCT01997346 - Multi-level Determinants of Starting ART Late: Aim 2 N/A
Active, not recruiting NCT01875952 - Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL) Phase 4
Completed NCT01199939 - A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients Phase 2
Completed NCT03783130 - Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults Phase 1
Active, not recruiting NCT05657106 - Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk N/A
Not yet recruiting NCT05727033 - Extraordinarily Fun Training Project in Compulsory Secondary Education - Sexually Transmitted Infections N/A
Completed NCT01053741 - Effect of Seminal Fluid on the Colon Wall; Implications for HIV Transmission N/A